
    
      Participants will undergo a telephone screening and then, within 4 weeks, complete an
      in-person screening visit to determine eligibility. Then, within 4 weeks they will be
      randomized to either OXT or placebo. After a minimum 1-week (7-28 days) "washout,"
      participants will cross-over to treatment with the other condition (i.e., placebo or OXT).
    
  